| 
             
			
			 The researchers asked three different pathologists to give a second 
			opinion on women's biopsy slides. When the slides showed either 
			invasive breast cancer, or harmless or benign cells, the doctors 
			agreed with the original diagnosis at least 97 percent of the time. 
			 
			But when the initial diagnosis was “atypia” – healthy cells that 
			grow faster than normal – the pathologists thought doctors had 
			originally overestimated the danger in more than half of cases. And 
			they thought doctors had overestimated the danger for almost one in 
			five women who were originally diagnosed with a common noninvasive 
			malignancy of the breast known as ductal carcinoma in situ (DCIS). 
			 
			"It's easier for physicians to diagnose diseases at the extremes of 
			the spectrum – we are good at diagnosing normal breast tissue and 
			the very abnormal cells of invasive breast cancer," said lead study 
			author Dr. Joann Elmore of the University of Washington School of 
			Medicine and Harborview Medical Center in Seattle. 
			 
			"Between these extremes, agreement of pathologists deteriorates," 
			Elmore added by email. 
			
			  
			Atypia and DCIS are gray areas on a spectrum of cancer severity 
			between benign, or generally harmless, cells and fast-growing 
			invasive tumors, said Dr. Richard Bleicher, breast clinical program 
			leader at Fox Chase Cancer Center in Philadelphia. 
			 
			"It's sort of akin to trying to differentiate blue from teal from 
			green – there is a bit of subjectivity," said Bleicher, who wasn't 
			involved in the study. 
			 
			For the study, three different pathologists working independently 
			reviewed one biopsy slide apiece from 240 women aged 50 to 59. 
			 
			Overall, they agreed with the original biopsy diagnosis about 92 
			percent of the time, Elmore and colleagues report in the Annals of 
			Internal Medicine. 
			 
			They thought about five percent of the original diagnoses had 
			overestimated the danger, and roughly 3 percent had underestimated 
			the cancer risk. 
			 
			In the real world, pathologists might have consulted with colleagues 
			or requested additional tissue samples if the diagnosis wasn’t clear 
			from one slide, potentially increasing the accuracy of diagnoses and 
			limiting the disagreement among doctors, the authors note. 
			 
			Still, the findings highlight the challenges doctors and patients 
			face in deciding the best course of action when results don’t fall 
			clearly into an extremely low-risk or high-risk category, Elmore 
			said. 
			
            [to top of second column]  | 
            
             
  
				
			Women with an abnormal mammogram may rush to get a biopsy, hoping 
			for an immediate resolution and a clear diagnosis, Elmore noted. But 
			when the biopsy results fall in a gray area, their path forward 
			isn't always as clear cut as they would like. 
			 
			"I encourage women who receive an initial diagnosis of either atypia 
			or DCIS to realize that they do not need to act immediately on the 
			results; they have time to obtain a second opinion to verify the 
			diagnosis," Elmore said. 
			 
			At the same time, women may find that even when doctors agree on the 
			diagnosis, they may not agree on treatment, Dr. Alexander Borowsky, 
			a researcher at the University of California, Davis, wrote in an 
			editorial. 
			When doctors overestimate the cancer risk, some women may suffer 
			side effects from treatment that probably didn't lower their odds of 
			dying from breast cancer, Bleicher noted. For example, some women 
			with atypia or DCIS may be given tamoxifen, a drug to treat or 
			prevent cancer that can also trigger early menopause. 
			 
			In the opposite circumstance, when doctors underestimate severity, 
			women may miss an opportunity to get radiation or chemotherapy at an 
			earlier stage of cancer when it may be more effective. 
			  
			
			  
			 
			"We have a critical need to validate the tools that diagnose 
			disease, especially these categories in the gray area between normal 
			and cancer," Elmore said. "Our results underscore persistent 
			difficulties with medical diagnoses based on clinical judgment." 
			 
			SOURCE: http://bit.ly/1i46lF7 Annals of Internal Medicine, online 
			March 21, 2016. 
			  
			[© 2016 Thomson Reuters. All rights 
				reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  |